MAP2K7 and malignant colon neoplasm: Treatment with MEK inhibitor PD0325901 markedly reduced MEK/ERK activity in BRAFV600E bearing colon cancer cell lines (Figure 3A, lanes 3, 7, 11), which was accompanied by a remarkable reduction of autophagic markers expression, particularly in LC3II (Figure 3A, 3D).